FDA proposes curbs on mass compounding of Novo and Lilly weight-loss drugs
Reuters reports the agency is moving to restrict large-scale compounded copies of semaglutide and tirzepatide.
DO
By Daniel Okafor · Regulatory Correspondent
Apr 30 03:00 ETSource: Reuters
The wire
- 01The FDA has proposed restrictions on mass compounding of weight-loss drugs marketed by Novo Nordisk and Eli Lilly, according to Reuters.
- 02503A and 503B pharmacies and the telehealth platforms that source from them face direct exposure if the proposal is finalized as described.
- 03The scope, comment period and effective date of the proposal, and how it treats personalized doses, remain to be spelled out.
From the source
Read at reuters.comUS FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs